Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

25 avr. 2024 08h00 HE | Source: Fibrobiologics, Inc.

FibroBiologics Plans to Collaborate with Charles River to Manufacture Fibroblast-based Spheroids

HOUSTON, April 25, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (Nasdaq: FBLG) ("FibroBiologics") and Charles River Laboratories (“Charles River”), a highly respected, global provider of drug...
11 avr. 2024 09h31 HE | Source: Fibrobiologics, Inc.

FibroBiologics Granted Patent for Regeneration of Cartilage-Type Cells by the Australian Patent Office

HOUSTON, April 11, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the...
04 avr. 2024 09h31 HE | Source: Fibrobiologics, Inc.

FibroBiologics Presents Data from Dermal Fibroblast Spheroid-based Treatment of Chronic Wounds in a Diabetes Mouse Model at Advanced Wound Care Summit USA

HOUSTON, April 04, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 150+ patents issued and pending for the development...
28 mars 2024 09h31 HE | Source: Fibrobiologics, Inc.

FibroBiologics Files Patent Application Covering Fibroblast-based Technology for the Potential Treatment of Lupus

HOUSTON, March 28, 2024 (GLOBE NEWSWIRE) -- FibroBiologics (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the...